Related references
Note: Only part of the references are listed.A Prospective Pilot Study of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Ruxolitinib in Patients with Myelofibrosis
Elena Vladislavovna Morozova et al.
ACTA HAEMATOLOGICA (2021)
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen
Patrizia Chiusolo et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
Fludarabine/Busulfan Conditioning-Based Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis: Role of Ruxolitinib in Improving Survival Outcomes
Saurabh Chhabra et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
Abraham S. Kanate et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2020)
Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications
Alessandra Malato et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2020)
Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study
Vikas Gupta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups
Makoto Murata et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Comparison of DIPSS and MYSEC-PM for prediction of outcome in post-PV and ET myelofibrosis after allogeneic stem-cell transplantation
Nico Gagelmann et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation
Nico Gagelmann et al.
BLOOD (2019)
State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019
Donal P. McLornan et al.
HAEMATOLOGICA (2019)
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Marie Robin et al.
HAEMATOLOGICA (2019)
Myeloablative and Reduced-Intensity Conditioned Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis: A Retrospective Study by the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
Donal McLornan et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Reduced-intensity conditioning allogeneic transplant with dual T-cell depletion in myelofibrosis
Maria Queralt Salas et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2019)
Family Mismatched Allogeneic Stem Cell Transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of European Society for Blood and Marrow Transplantation
Kavita Raj et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group
Francesca Patriarca et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Allogeneic hematopoietic stem cell transplant overcomes the adverse survival effect of very high risk and unfavorable karyotype in myelofibrosis
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes
Bethany T. Samuelson Bannow et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT
Donal P. McLornan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis
Sharifah Shahnaz Syed Abd Kadir et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2018)
MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis
Paola Guglielmelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet
Tiziano Barbuil et al.
LEUKEMIA (2018)
Driver mutations and prognosis in primary myelofibrosis: Mayo-Careggi MPN alliance study of 1,095 patients
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Low-dose splenic irradiation prior to hematopoietic cell transplantation in hypersplenic patients with myelofibrosis
Noah S. Kalman et al.
LEUKEMIA & LYMPHOMA (2017)
Risk factors and a prognostic model for postsplenectomy survival in myelofibrosis
Ayalew Tefferi et al.
AMERICAN JOURNAL OF HEMATOLOGY (2017)
Impact of molecular residual disease post allografting in myelofibrosis patients
C. Wolschke et al.
BONE MARROW TRANSPLANTATION (2017)
Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Nicolaus Kroeger et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation
Marie Robin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Chronic and Advanced Phase Myelofibrosis
Alla Keyzner et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors
Stefania Bregante et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis
Marie Robin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis
Nicolaus Kroeger et al.
BLOOD (2015)
Effect of conditioning regimens on graft failure in myelofibrosis: a retrospective analysis
S. Slot et al.
BONE MARROW TRANSPLANTATION (2015)
Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies
R. F. Olsson et al.
LEUKEMIA (2015)
Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant Research
Vikas Gupta et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Unrelated Cord Blood Transplantation for Patients with Primary or Secondary Myelofibrosis
Marie Robin et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
CD34 Selected Cells for the Treatment of Poor Graft Function after Allogeneic Stem Cell Transplantation
Alessandra Stasia et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis
Damiano Rondelli et al.
BLOOD (2014)
Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation
V. Panagiota et al.
LEUKEMIA (2014)
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation
Fabio P. S. Santos et al.
LEUKEMIA & LYMPHOMA (2014)
Splenic Irradiation and a Reduced-Intensity Conditioning Regimen Prior to Allogeneic Stem-Cell Transplantation for Myelofibrosis
Ojas H. Vyas et al.
BLOOD (2014)
Effects of spleen status on early outcomes after hematopoietic cell transplantation
G. Akpek et al.
BONE MARROW TRANSPLANTATION (2013)
Ruxolitinib Before Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Patients With myelofibrosis : a Preliminary Descriptive Report Of The JAK ALLO Study, a Phase II Trial Sponsored By Goelams-FIM In Collaboration With The Sfgmtc
Marie Robin et al.
BLOOD (2013)
The outcome of allo-HSCT for 92 patients with myelofibrosis in the Nordic countries
J. Abelsson et al.
BONE MARROW TRANSPLANTATION (2012)
Donor lymphocyte infusions and second transplantation as salvage treatment for relapsed myelofibrosis after reduced-intensity allografting
Evgeny Klyuchnikov et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Risk models predicting survival after reduced-intensity transplantation for myelofibrosis
Haefaa Alchalby et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
Claire Harrison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)
Marie Robin et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status
Naseema Gangat et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
HOW TO MANAGE ... How I treat splenomegaly in myelofibrosis
F. Cervantes
BLOOD CANCER JOURNAL (2011)
Outcome of Transplantation for Myelofibrosis
Karen K. Ballen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2010)
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)
Francesco Passamonti et al.
BLOOD (2010)
Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
Haefaa Alchalby et al.
BLOOD (2010)
Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type
A. Bacigalupo et al.
BONE MARROW TRANSPLANTATION (2010)
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation
E. Rumi et al.
BONE MARROW TRANSPLANTATION (2010)
Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT
H. Alchalby et al.
BONE MARROW TRANSPLANTATION (2010)
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment
Francisco Cervantes et al.
BLOOD (2009)
Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Nicolaus Kroeger et al.
BLOOD (2009)
A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis
V. Gupta et al.
BONE MARROW TRANSPLANTATION (2009)
Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO)
Francesca Patriarca et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis
Markus Ditschkowski et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2006)
Pilot study of reduced-intensity conditioning followed by allogeneic stem cell transplantation from related and unrelated donors in patients with myelofibrosis
N Kröger et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients
A Tefferi et al.
BLOOD (2000)
Share Paper
